Dosing & Uses
Dosage Forms & Strengths
tablet
- 0.2mg
Opioid-induced Constipation
Indicated for opioid-induced constipation (OIC) in adults with chronic noncancer pain
0.2 mg PO qDay
Also see Administration
Dosage Modifications
Hepatic impairment
- Mild or moderate (Child-Pugh A or B): No dose adjustment required
- Severe (Child-Pugh C): Avoid use
Safety and efficacy not established
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
>10%
Abdominal pain (8-11%)
1-10%
Diarrhea (7%)
Nausea (4-6%)
Vomiting (3%)
Gastroenteritis (2-3%)
Opioid withdrawal (1-3%)
Frequency Not Defined
Bronchospasm
Rash
Warnings
Contraindications
Known or suspected GI obstruction and patients at increased risk of recurrent obstruction, owing to the potential for GI perforation
History of hypersensitivity to naldemedine; bronchospasm and rash reported
Cautions
Gastrointestinal perforation
- GI perforation reported with use of another PAMORA in patients with conditions that may be associated with localized or diffuse reduction of structural integrity in the wall of the GI tract (eg, peptic ulcer disease, Ogilvie syndrome, diverticular disease, infiltrative GI tract malignancies, peritoneal metastases)
- Consider risk with use in patients with these conditions or other conditions that might result in impaired integrity of the GI tract wall (eg, Crohn disease)
- Monitor for severe, persistent, or worsening abdominal pain and discontinue naldemedine in patients who develop this symptom
Opioid withdrawal
- Clusters of symptoms consistent with opioid withdrawal include hyperhidrosis, chills, increased lacrimation, hot flush/flushing, pyrexia, sneezing, feeling cold, abdominal pain, diarrhea, nausea, and vomiting
- Patients with blood-brain barrier disruption may be at increased risk for opioid withdrawal or reduced analgesia
- Take into account the overall risk-benefit profile when prescribing naldemedine in such patients
- Monitor for symptoms of opioid withdrawal
Drug interaction overview
- Substrate of CYP3A4 (major), P-gp, and UGT1A3 (minor)
- Opioid antagonists: Avoid use with another opioid antagonist
- Strong CYP3A4 inducers: Avoid coadministration, owing to potential for decreased efficacy of naldemedine
- Moderate or strong CYP3A4 inhibitors: Monitor for potential naldemedine adverse effects, owing to increased plasma concentrations
- P-gp inhibitors: Monitor for potential naldemedine adverse effects, owing to increased plasma concentrations
Pregnancy
Pregnancy
Fetal/neonatal clinical considerations
- Naldemedine crosses the placenta and may precipitate opioid withdrawal in a fetus or newborn, owing to the immature fetal blood-brain barrier
- There are no available data with naldemedine in pregnant women to inform a drug-associated risk of major birth defects and miscarriage
Lactation
Unknown if distributed in human breast milk
Naldemedine was present in the milk of rats
Because of the potential for serious adverse reactions, including opioid withdrawal in breastfed infants, a decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother
If drug is discontinued in order to minimize drug exposure to a breastfed infant, advise women that breastfeeding may be resumed 3 days after the final dose
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Opioid antagonist with binding affinities for mu-, delta-, and kappa-opioid receptors
Functions as a peripherally acting mu-opioid receptor antagonist (PAMORA) in tissues such as the GI tract, thereby decreasing the constipating effects of opioids
Derivative of naltrexone to which a side chain has been added that increases the molecular weight and the polar surface area, thereby reducing its ability to cross the blood-brain barrier
Absorption
Peak plasma concentrations: 45 minutes (fasting); 2.5 hr (high-fat meal)
A high-fat meal decreased the rate, but not the extent of absorption
Distribution
Protein bound: 93-94%
Vd: 155 L
Metabolism
Primarily metabolized by CYP3A4 to nor-naldemedine, with minor contribution from UGT1A3 to form naldemedine 3-G
Nor-naldemedine and naldemedine 3-G have been shown to have antagonistic activity for opioid receptors, with less potent effect than naldemedine
Naldemedine also undergoes cleavage in the GI tract to form benzamidine and naldemedine carboxylic acid
Elimination
Half-life: 11 hr
Excretion: 57% urine; 35% feces
Administration
Oral Administration
May take with or without food
Alteration of analgesic dosing regimen before initiating naldemedine is not required
Patients receiving opioids for <4 weeks may be less responsive to naldemedine
Discontinue naldemedine if treatment with opioids is also discontinued
Storage
Store in light-resistant container at 20-25°C (68-77°F); excursions permitted to 15-30°C (59-86°F)
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.